BMC infectious diseases · 2026
Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial.
СтатьяМногоцентровое исследованиеКлиническое исследование II фазыРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Yihong, Qin Yuanyuan, Liu Xia, Zhao Qingxia, Wang Min, Chen Yuanyuan, Li Ying, He Kun, Li Xiaofeng, Harypursat Vijay, Xie Dong, Chen Yaokai
Аннотация
BACKGROUND: Albuvirtide (ABT), a fusion inhibitor, and 3BNC117, a broadly neutralizing antibody, were evaluated for efficacy and safety in combination with an optimized background regimen (OBR) in adults with multidrug-resistant (MDR) HIV-1.
METHODS: In this phase 2 trial conducted in China via an international collaborative screening effort, we enrolled MDR HIV-1 patients with prior treatment failures and baseline viral loads > 1000 copies/mL. After a 6-day control period on existing therapy, participants received 3BNC117 on day 7 and ABT on days 7-9. On day 14, eligible patients were randomized 1:1 to Group A (ABT once weekly and 3BNC117 once every two weeks) or Group B (ABT and 3BNC117 once every two weeks), each with an OBR containing at least one fully active drug, for 24 weeks. The primary endpoint was the proportion with ≥ 0.5 log10 viral load reduction from day 7 to 14.
RESULTS: Sixteen patients completed the study. Baseline mean viral load was 4.47 log10 copies/mL, and mean CD4 + T-cell count was 165 cells/µL. By day 14, 62.5% showed a ≥ 0.5 log10 reduction from day 7 (p = 0.012 vs. control), with a mean drop of 1.05 log10. At end of treatment (EOT), the mean decrease was 2.82 log10, and 87.5% had viral load < 50 copies/mL. Viral load < 50 copies/mL was seen in 75% of Group A and 100% of Group B. No deaths or serious ABT+3BNC117-related adverse events were reported.
CONCLUSIONS: In patients with MDR HIV-1 infection who have limited treatment therapeutic options, the combination of ABT+3BNC117 plus an OBR was observed to have significant antiviral activity during a 34-week study period.
TRIAL REGISTRATION: Clinicaltrials.gov NCT04560569, Sep 23, 2020.
METHODS: In this phase 2 trial conducted in China via an international collaborative screening effort, we enrolled MDR HIV-1 patients with prior treatment failures and baseline viral loads > 1000 copies/mL. After a 6-day control period on existing therapy, participants received 3BNC117 on day 7 and ABT on days 7-9. On day 14, eligible patients were randomized 1:1 to Group A (ABT once weekly and 3BNC117 once every two weeks) or Group B (ABT and 3BNC117 once every two weeks), each with an OBR containing at least one fully active drug, for 24 weeks. The primary endpoint was the proportion with ≥ 0.5 log10 viral load reduction from day 7 to 14.
RESULTS: Sixteen patients completed the study. Baseline mean viral load was 4.47 log10 copies/mL, and mean CD4 + T-cell count was 165 cells/µL. By day 14, 62.5% showed a ≥ 0.5 log10 reduction from day 7 (p = 0.012 vs. control), with a mean drop of 1.05 log10. At end of treatment (EOT), the mean decrease was 2.82 log10, and 87.5% had viral load < 50 copies/mL. Viral load < 50 copies/mL was seen in 75% of Group A and 100% of Group B. No deaths or serious ABT+3BNC117-related adverse events were reported.
CONCLUSIONS: In patients with MDR HIV-1 infection who have limited treatment therapeutic options, the combination of ABT+3BNC117 plus an OBR was observed to have significant antiviral activity during a 34-week study period.
TRIAL REGISTRATION: Clinicaltrials.gov NCT04560569, Sep 23, 2020.